

Christof M Kramm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4797871/publications.pdf>

Version: 2024-02-01

78
papers

8,755
citations

117625

34
h-index

74163

75
g-index

79
all docs

79
docs citations

79
times ranked

11839
citing authors

#	ARTICLE	IF	CITATIONS
1	Magnetic Resonance Imaging Characteristics of Molecular Subgroups in Pediatric H3K27M Mutant Diffuse Midline Glioma. <i>Clinical Neuroradiology</i> , 2022, 32, 249-258.	1.9	8
2	HGG-21. Oncogenic tyrosine kinase gene fusions in infant-type hemispheric gliomas - comparison of RNA- and DNA-based methods for their reliable detection. <i>Neuro-Oncology</i> , 2022, 24, i65-i65.	1.2	0
3	Biology and grading of pleomorphic xanthoastrocytoma – what have we learned about it?. <i>Brain Pathology</i> , 2021, 31, 20-32.	4.1	32
4	Complementary and alternative medicine in children with diffuse intrinsic pontine glioma – A SIOPE DIPG Network and Registry study. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29061.	1.5	4
5	PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. <i>Acta Neuropathologica</i> , 2021, 142, 841-857.	7.7	36
6	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. <i>Cancer Discovery</i> , 2021, 11, 2764-2779.	9.4	110
7	Spontaneous regression of a congenital high-grade glioma – a case report. <i>Neuro-Oncology Advances</i> , 2021, 3, v120.	0.7	1
8	GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. <i>Acta Neuropathologica</i> , 2021, 142, 1065-1069.	7.7	16
9	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. <i>Cancer Discovery</i> , 2020, 10, 942-963.	9.4	157
10	HGG-34. DETECTION OF ONCOGENIC FUSION EVENTS IN SUPRATENTORIAL GLIOBLASTOMAS OF YOUNG CHILDREN. <i>Neuro-Oncology</i> , 2020, 22, iii349-iii350.	1.2	0
11	The German National Registry of Primary Immunodeficiencies (2012–2017). <i>Frontiers in Immunology</i> , 2019, 10, 1272.	4.8	71
12	Desmoplastic small round cell tumors: Multimodality treatment and new risk factors. <i>Cancer Medicine</i> , 2019, 8, 527-542.	2.8	39
13	Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. <i>European Journal of Cancer</i> , 2019, 114, 27-35.	2.8	51
14	Impact of rs12917 MGMT Polymorphism on [18F]FDG-PET Response in Pediatric Hodgkin Lymphoma (PHL). <i>Molecular Imaging and Biology</i> , 2019, 21, 1182-1191.	2.6	0
15	Occurrence of high-grade glioma in Noonan syndrome: Report of two cases. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27625.	1.5	11
16	Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series. <i>Oncologist</i> , 2019, 24, e921-e929.	3.7	19
17	The landscape of genomic alterations across childhood cancers. <i>Nature</i> , 2018, 555, 321-327.	27.8	1,068
18	Diffuse intrinsic pontine gliomas (DIPG) at recurrence: is there a window to test new therapies in some patients?. <i>Journal of Neuro-Oncology</i> , 2018, 139, 501-501.	2.9	2

#	ARTICLE	IF	CITATIONS
19	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	27.8	1,872
20	Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatin-based polychemotherapy regimen. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 215-224.	2.0	11
21	Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. <i>Neuro-Oncology</i> , 2018, 20, 123-131.	1.2	184
22	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. <i>Journal of Clinical Oncology</i> , 2018, 36, 1963-1972.	1.6	250
23	Transcriptomic and epigenetic profiling of diffuse midline gliomas, H3 K27M-mutant discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location. <i>Acta Neuropathologica Communications</i> , 2018, 6, 117.	5.2	83
24	A suggestion to introduce the diagnosis of diffuse midline glioma of the pons, H3 K27 wildtype (WHO) Tj ETQq0.0 0 rgBTj/Overlock	7.7	13
25	Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. <i>Journal of Neuro-Oncology</i> , 2017, 132, 255-266.	2.9	42
26	The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease. <i>Journal of Neuro-Oncology</i> , 2017, 132, 323-331.	2.9	27
27	Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOPE-HGG/DIPG working group. <i>European Journal of Cancer</i> , 2017, 73, 38-47.	2.8	101
28	Childhood cancer predisposition syndromes: A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 1017-1037.	1.2	200
29	H3-IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. <i>Acta Neuropathologica</i> , 2017, 134, 507-516.	7.7	144
30	The β -catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner. <i>Oncotarget</i> , 2017, 8, 27300-27313.	1.8	35
31	High-grade glioma in very young children: a rare and particular patient population. <i>Oncotarget</i> , 2017, 8, 64564-64578.	1.8	38
32	Snail homolog 1 is involved in epithelial-mesenchymal transition-like processes in human glioblastoma cells. <i>Oncology Letters</i> , 2017, 13, 3882-3888.	1.8	11
33	Pediatric Colorectal Carcinoma is Associated With Excellent Outcome in the Context of Cancer Predisposition Syndromes. <i>Pediatric Blood and Cancer</i> , 2016, 63, 611-617.	1.5	22
34	Next-generation personalised medicine for high-risk paediatric cancer patients: The INFORM pilot study. <i>European Journal of Cancer</i> , 2016, 65, 91-101.	2.8	262
35	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. <i>Cell</i> , 2016, 164, 1060-1072.	28.9	702
36	Lenalidomide in an in vitro Dendritic Cell Model for Malignant Gliomas. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2016, 16, 1468-1473.	1.7	2

#	ARTICLE	IF	CITATIONS
37	Characterization of an Additional Splice Acceptor Site Introduced into CYP4B1 in Hominoidea during Evolution. PLoS ONE, 2015, 10, e0137110.	2.5	13
38	Secondary Solid Malignancies After High-Grade Glioma Treatment in Pediatric Patients. Pediatric Hematology and Oncology, 2015, 32, 467-473.	0.8	3
39	Identification of amino acid determinants in CYP4B1 for optimal catalytic processing of 4-ipomeanol. Biochemical Journal, 2015, 465, 103-114.	3.7	46
40	External validation of a prognostic model estimating the survival of patients with recurrent high-grade gliomas after reirradiation. Practical Radiation Oncology, 2015, 5, e143-e150.	2.1	12
41	Strategies to improve the quality of survival for childhood brain tumour survivors. European Journal of Paediatric Neurology, 2015, 19, 619-639.	1.6	36
42	Genetic Analysis of Diffuse High-Grade Astrocytomas in Infancy Defines a Novel Molecular Entity. Brain Pathology, 2015, 25, 409-417.	4.1	32
43	Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. Neuro-Oncology, 2015, 17, 160-166.	1.2	124
44	Reirradiation as part of a salvage treatment approach for progressive non-pontine pediatric high-grade gliomas: preliminary experiences from the German HIT-HGG study group. Radiation Oncology, 2014, 9, 177.	2.7	16
45	Impact of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine resistance of Hodgkin's lymphoma cells. Leukemia Research, 2014, 38, 138-143.	0.8	26
46	CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapy. Cancer Immunology, Immunotherapy, 2013, 62, 1797-1809.	4.2	19
47	H3F3A K27M Mutation in Pediatric CNS Tumors. American Journal of Clinical Pathology, 2013, 139, 345-349.	0.7	116
48	Impact of Chemotherapy for Childhood Leukemia on Brain Morphology and Function. PLoS ONE, 2013, 8, e78599.	2.5	63
49	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. Cancer Cell, 2012, 22, 425-437.	16.8	1,551
50	Pediatric high grade glioma of the spinal cord: results of the HIT-GBM database. Journal of Neuro-Oncology, 2012, 107, 139-146.	2.9	29
51	Thalamic high-grade gliomas in children: a distinct clinical subset?. Neuro-Oncology, 2011, 13, 680-689.	1.2	64
52	Clinical and epidemiological characteristics of pediatric gliosarcomas. Journal of Neuro-Oncology, 2010, 97, 257-265.	2.9	25
53	Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM protocol. Cancer, 2010, 116, 705-712.	4.1	116
54	Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatric Blood and Cancer, 2010, 54, 519-525.	1.5	120

#	ARTICLE	IF	CITATIONS
55	Tumor vaccination for high-grade glioma. <i>Pediatric Blood and Cancer</i> , 2010, 55, 1437-1437.	1.5	1
56	A Pyrosequencing-Based Assay for the Rapid Detection of IDH1 Mutations in Clinical Samples. <i>Journal of Molecular Diagnostics</i> , 2010, 12, 750-756.	2.8	53
57	Pediatric giant cell glioblastoma: New insights into a rare tumor entity. <i>Neuro-Oncology</i> , 2009, 11, 323-329.	1.2	16
58	Anaplastic ganglioglioma in children. <i>Journal of Neuro-Oncology</i> , 2009, 92, 157-163.	2.9	50
59	Subpopulations of malignant gliomas in pediatric patients: analysis of the HIT-GBM database. <i>Journal of Neuro-Oncology</i> , 2008, 87, 155-164.	2.9	42
60	Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. <i>Journal of Neuro-Oncology</i> , 2008, 90, 309-314.	2.9	44
61	Comparable Long-Term Survival after Bone Marrow versus Peripheral Blood Progenitor Cell Transplantation from Matched Unrelated Donors in Children with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1338-1345.	2.0	38
62	Value of surrogate tests to predict exercise-induced bronchoconstriction in atopic childhood asthma. <i>Pediatric Pulmonology</i> , 2007, 42, 225-230.	2.0	34
63	Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. <i>Oncogene</i> , 2005, 24, 1231-1243.	5.9	97
64	A Neuroblastoma-Selective Suicide Gene Therapy Approach Using the Tyrosine Hydroxylase Promoter. <i>Pediatric Research</i> , 2004, 56, 268-277.	2.3	9
65	Recurrent Atrial Ectopic Tachycardia Following Chemotherapy with Ifosfamide. <i>Pediatric Hematology and Oncology</i> , 2004, 21, 307-311.	0.8	6
66	Transduction of human glial and neuronal tumor cells with different lentivirus vector pseudotypes. <i>Journal of Neuro-Oncology</i> , 2004, 70, 281-288.	2.9	30
67	Treatment of vincristine-induced bilateral ptosis with pyridoxine and pyridostigmine. <i>Pediatric Blood and Cancer</i> , 2004, 42, 287-288.	1.5	35
68	Expression of mutant non-cleavable Fas ligand on retrovirus packaging cells causes apoptosis of immunocompetent cells and improves prodrug activation gene therapy in a malignant glioma model. <i>Life Sciences</i> , 2003, 73, 1847-1860.	4.3	13
69	Unexpected high serum levels of tacrolimus after a single topical application in an infant. <i>Journal of Pediatrics</i> , 2003, 143, 280.	1.8	6
70	Alternative Concepts of Suicide Gene Therapy for Graft-versus-Host Disease after Adoptive Immunotherapy. <i>Acta Haematologica</i> , 2003, 110, 132-138.	1.4	2
71	Stable Transgenic Expression of IL-2 and HSV1-tk by Single and Fusion Tumor Cell Lines Bearing EWS/FLI-1 Chimeric Genes. <i>Pediatric Hematology and Oncology</i> , 2003, 20, 119-140.	0.8	9
72	Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: Implications for pharmacogene therapy. <i>Cancer Gene Therapy</i> , 2002, 9, 178-188.	4.6	17

#	ARTICLE	IF	CITATIONS
73	Vector Delivery Methods and Targeting Strategies for Gene Therapy of Brain Tumors. <i>Current Gene Therapy</i> , 2001, 1, 367-383.	2.0	54
74	Infectious complications in children with acute lymphoblastic leukemia and T-cell lymphoma – a rationale for tailored supportive care. <i>Supportive Care in Cancer</i> , 2001, 9, 514-521.	2.2	27
75	Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma. <i>Cancer Gene Therapy</i> , 2001, 8, 662-668.	4.6	48
76	Enhanced green fluorescent protein fusion proteins of herpes simplex virus type 1 thymidine kinase and cytochrome P450 4B1: Applications for prodrug-activating gene therapy. <i>Cancer Gene Therapy</i> , 2000, 7, 806-812.	4.6	33
77	Improved method for transport of living cell cultures. <i>Biotechnology Letters</i> , 2000, 22, 383-385.	2.2	3
78	Bcl-2 expression in higher-grade human glioma: a clinical and experimental study. <i>Journal of Neuro-Oncology</i> , 2000, 48, 207-216.	2.9	53